Should CKD Be a Coronary Heart Disease Risk Equivalent?
Refers to article:
The Impact of Reclassifying Moderate CKD as a Coronary Heart Disease Risk Equivalent on the Number of US Adults Recommended Lipid-Lowering Treatment
, 12 December 2006
Amanda D. Hyre, Caroline S. Fox, Brad C. Astor, Andrew J. Cohen, Paul Muntner
American Journal of Kidney Diseases
January 2007 (Vol. 49, Issue 1, Pages 37-45) Abstract |
Full Text |
Full-Text PDF (321 KB)
No abstract is available. To read the body of this article, please view the Full Text online.
Departments of Medicine, Critical Care, and Public Health Sciences, Institute of Health Economics, University of Alberta, Edmonton, Canada
No reprints will be available. All correspondence to Marcello Tonelli, MD, 7-129 Clinical Sciences Bldg, 8440-112 St, Edmonton, Alberta T6G 2G3, Canada.
Support: Dr Tonelli was supported by salary awards from the Canadian Institutes of Health Research and the Alberta Heritage Foundation for Medical Research. Potential conflicts of interest: Dr Tonelli received a research grant (>$10,000) from Bristol-Myers-Squibb in 2003, served on a Pfizer advisory board in 2004, received honoraria (<$10,000) from Pfizer for continuing medical education lectures in 2004-2005, and received a research grant from AstraZeneca (<$10,000) in 2005. Honoraria (<$10,000) provided by Merck and Astra-Zeneca for academic grand rounds given in 2006 were donated directly to charity.
